USE OF ARYL AND HETARYL CARBOXAMIDES AS ENDOPARASITICIDES

摘要

The present application relates to known and novel aryl- and hetarylcarboxamides of the formula (I);;and to their use as medicaments for controlling endoparasites in animals or humans, and also to parasiticidal compositions, in particular endoparasites, comprising aryl- and hetarylcyclylcarboxamides.

主权项

1. A compound of formula (I) in which X represents mono- or poly-M1-substituted phenyl, thienyl or furanyl; Q represents mono- or poly-M1-substituted pyridyl, thienyl, furanyl or isothiazolyl; Y represents hydrogen or represents optionally mono- or poly-M2-substituted (C1-C10)-alkyl, (C2-C10)-alkenyl, (C2-C10)-alkynyl, (C1-C10)-haloalkyl, (C2-C10)-haloalkenyl, (C2-C10)-haloalkynyl, (C1-C10)-alkoxy, (C2-C10)-alkenyloxy, (C3-C10)-alkynyloxy, (C3-C14)-cycloalkyl-(C1-C10)-alkyl or represents an optionally mono- or poly-M2-substituted 3- to 14-membered cyclic group; W represents oxygen or sulfur; L1 represents —C(R11, R12)—, oxygen, sulfur or —N(R1)—; L2 represents —C(R21, R22)—; L3 represents —C(R31, R32)— or a direct bond; M1 represents hydrogen, halogen, cyano, nitro, OH, (C1-C10)-alkyl, (C1-C10)-haloalkyl, (C1-C10)-alkoxy, (C1-C10)-haloalkoxy, (C1-C10)-alkylthio, (C1-C10)-haloalkylthio, (C1-C10)-alkylsulfonyl, (C1-C10)-haloalkylsulfonyl, (C1-C10)-alkylsulfanyl, (C1-C10)-haloalkylsulfanyl, (3- to 14-membered cyclic group)-O—; R1 represents hydrogen or optionally mono- or poly-M2-substituted (C1-C10)-alkyl, (C2-C10)-alkenyl, (C2-C10)-alkynyl, (C1-C10)-haloalkyl, (C2-C10)-haloalkenyl, (C2-C10)-haloalkynyl, (C3-C10)-cycloalkyl-(C1-C10)-alkyl or represents an optionally mono- or poly-M2-substituted 3- to 14-membered cyclic group; R11, R12 each independently of one another represent hydrogen, halogen or optionally mono- or poly-M2-substituted (C1-C10)-alkyl, (C2-C10)-alkenyl, (C2-C10)-alkynyl, (C1-C10)-haloalkyl, (C2-C10)-haloalkenyl, (C2-C10)-haloalkynyl, (C1-C10)-alkoxy, (C2-C10)-alkenyloxy, (C3-C10)-alkynyloxy, (C3-C14)-cycloalkyl-(C1-C10)-alkyl or represents an optionally mono- or poly-M2-substituted 3- to 14-membered cyclic group; R11, R12 together represent an optionally mono- or poly-M2-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; R21, R22 each independently of one another represent hydrogen, halogen or optionally mono- or poly-M2-substituted (C1-C10)-alkyl, (C2-C10)-alkenyl, (C2-C10)-alkynyl, (C1-C10)-haloalkyl, (C2-C10)-haloalkenyl, (C2-C10)-haloalkynyl, (C1-C10)-alkoxy, (C1-C10)-haloalkoxy, (C2-C10)-alkenyloxy, (C3-C10)-alkynyloxy, (C3-C14)-cycloalkyl-(C1-C10)-alkyl or represent an optionally mono- or poly-M2-substituted 3- to 14-membered cyclic group; R21, R22 together represent an optionally mono- or poly-M2-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; R31, R32 each independently of one another represent hydrogen or optionally mono- or poly-M2-substituted (C1-C10)-alkyl, (C2-C10)-alkenyl, (C2-C10)-alkynyl, (C1-C10)-haloalkyl, (C2-C10)-haloalkenyl, (C2-C10)-haloalkynyl, (C3-C14)-cycloalkyl-(C1-C10)-alkyl or represent an optionally mono- or poly-M2-substituted 3- to 14-membered cyclic group; R31, R32 together represent an optionally mono- or poly-M2-substituted spiro-attached 3- to 14-membered carbo- or 3- to 10-membered heterocyclic group; M2 each independently of one another represent halogen, formyl, cyano, nitro, (C1-C10)-alkyl, (C1-C10)-haloalkyl, (C2-C10)-alkenyl, (C2-C10)-haloalkenyl, (C2-C10)-alkynyl, (C2-C10)-haloalkynyl, (C1-C10)-alkoxy, (C1-C10)-haloalkoxy, (C2-C10)-alkenyloxy, (C2-C10)-haloalkenyloxy, (C3-C10)-alkynyloxy, (C3-C10)-haloalkynyloxy, (C1-C10)-alkylthio, (C1-C10)-haloalkylthio, (C2-C10)-alkenylthio, (C2-C10)-haloalkenylthio, (C3-C10)-alkynylthio, (C3-C10)-haloalkynylthio, (C1-C10)-alkylsulfonyl, (C1-C10)-haloalkylsulfonyl, (C2-C10)-alkenylsulfonyl, (C2-C10)-haloalkenylsulfonyl, (C3-C10)-alkynylsulfonyl, (C3-C10)-haloalkynylsulfonyl, (C1-C10)-alkylsulfanyl, (C1-C10)-haloalkylsulfanyl, (C2-C10)-alkenylsulfanyl, (C2-C10)-haloalkenylsulfanyl, (C3-C10)-alkynylsulfanyl, (C3-C10)-haloalkynylsulfanyl, (C1-C10)-alkylcarbonyl, (C1-C10)-haloalkylcarbonyl, (C2-C10)-alkenylcarbonyl, (C2-C10)-haloalkenylcarbonyl, (C2-C10)-alkynylcarbonyl, (C2-C10)-haloalkynylcarbonyl, (C1-C10)-alkoxycarbonyl, (C1-C10)-haloalkoxycarbonyl, (C2-C10)-alkenyloxycarbonyl, (C2-C10)-haloalkenyloxycarbonyl, (C3-C10)-alkynyloxycarbonyl, (C3-C10)-haloalkynyloxycarbonyl, (C1-C10)-alkylcarbonyloxy, (C1-C10)-haloalkylcarbonyloxy, (C2-C10)-alkenylcarbonyloxy, (C2-C10)-haloalkenylcarbonyloxy, (C2-C10)-alkynylcarbonyloxy, (C2-C10)-haloalkynylcarbonyloxy, a 3- to 14-membered cyclic group; And/or a salt, N-oxide and/or tautomeric form thereof; capable of being used as medicament for controlling one or more endoparasites in an animal and/or human.